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Abstract
Background: The demands of microarray expression technologies for quantities of RNA place a limit on the
questions they can address. As a consequence, the RNA requirements have reduced over time as technologies
have improved. In this paper we investigate the costs of reducing the starting quantity of RNA for the Illumina
BeadArray platform. This we do via a dilution data set generated from two reference RNA sources that have
become the standard for investigations into microarray and sequencing technologies.
Results: We find that the starting quantity of RNA has an effect on observed intensities despite the fact that the
quantity of cRNA being hybridized remains constant. We see a loss of sensitivity when using lower quantities of
RNA, but no great rise in the false positive rate. Even with 10 ng of starting RNA, the positive results are reliable
although many differentially expressed genes are missed. We see that there is some scope for combining data
from samples that have contributed differing quantities of RNA, but note also that sample sizes should increase to
compensate for the loss of signal-to-noise when using low quantities of starting RNA.
Conclusions: The BeadArray platform maintains a low false discovery rate even when small amounts of starting
RNA are used. In contrast, the sensitivity of the platform drops off noticeably over the same range. Thus, those
conducting experiments should not opt for low quantities of starting RNA without consideration of the costs of
doing so. The implications for experimental design, and the integration of data from different starting quantities,
are complex.
Background
Gene expression microarrays have become a routine
analysis tool; from their introduction [1] to recent head-
line publications [2-4] their widening use has been pri-
marily down to better understanding of how to design
[5,6], use and analyse [7,8] microarray experiments. An
important, if somewhat forgotten, design issue has been
the amount of starting material needed to produce high
quality microarray data. Ten years ago, around 10 μgo f
total RNA was required and even three years ago many
labelling protocols required 1 μg. The introduction of
Illumina BeadChips with a standard labelling reaction
requiring only 250 ng of total RNA made analysis of
some previously unconsidered sample types possible;
e.g. limited clinical samples or samples requiring consid-
erable microdissection and pooling.
Whilst many researchers continue to push the limits
of starting materials [9], development of robust standard
labelling protocols has further decreased the amount of
RNA required for microarrays. Until recently 250 ng of
starting mRNA was recommended for the Illumina Bea-
dArray platform. Now 50 ng to 100 ng is suggested
http://www.illumina.com/technology/direct_hybridizatio-
n_assay.ilmn. If one can indeed use so little starting
material then this is of tremendous importance in terms
of the scope of experiments that become possible. How-
ever, there is a wealth of literature that is based upon
250 ng, and it is important that future results are com-
parable to those obtained previously. One small compar-
i s o nh a sp r e v i o u s l yb e e nm a d e[ 1 0 ] .T h i ss t u d yf o u n d
that reproducible signal was obtainable from as little as
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the costs of such an approach.
Microarray dilution experiments [11,12], where two
samples are mixed together in a number of differing
(known) ratios and those mixtures hybridized to arrays,
have proven to be valuable tools for the comparison and
investigation of microarray platforms, most notably in
t h eM A Q Cp r o j e c t[ 1 3 ] .W ee m p l o yan i n e - l e v e ld i l u -
tion design to investigate the effect of changing the
quantity of starting mRNA on the performance of Illu-
mina BeadArrays. We consider the previously recom-
mended level of 250 ng, the current recommended
levels of 100 ng and 50 ng and one other (10 ng).
Here, we examine the costs and consequences of redu-
cing the amount of starting RNA, with consideration for
the issues of experimental design and meta-analysis,
while also providing a unique bead-level dilution experi-
ment to serve as a public resource to the Illumina-using
community. We use the Illumina HumanWG-6 V3 Bea-
dArray, analysed at the bead-level as we have previously
recommended [14]. One of the benefits of using the
bead-level data is that we can analyse separately the two
array-sections assigned to any one sample, thus allowing
inferences to be made about the more flexible HT12 Bea-
dArrays also. In addition to our purposes, we are creating
au n i q u ep u b l i cr e s o u r c e ,a n dhave designed our experi-
ment to be generally useful to the community.
Methods
Experimental Design
Six samples can be hybridized to the Illumina HumanWG-
6 V3 chip, each sample on two array-sections of approxi-
mately 1, 000, 000 beads that are distributed amongst
approximately 50, 000 bead-types. We treat the two
sections as separate arrays for the purposes of analysis,
due to previously observed inter-section differences
[14,15]. This also has the effect of making our results
comparable to those one might expect from the Illumina
HT-12 array which takes 12 samples, allocated one section
each.
We have used two reference RNA samples, previously
employed in the MAQC study [13], which have subse-
quently become a standard for microarray [16] and
next-generation sequencing [17] studies. These are the
Stratagene Universal Human Reference RNA (hereafter
“UHRR”), and the Ambion Human Brain Reference
RNA (hereafter “Brain”). Nine levels of mixture, includ-
ing the four employed in the first MAQC study, were
then created. These are 100:0, 99:1, 95:5, 90:10, 75:25,
50:50, 25:75, 10:90 and 0:100, where mixtures are pre-
sented as UHRR:Brain.
These nine levels allow for investigation of broad
trends, and for the detection of subtle differences. Com-
bined with the four levels of starting material that we
are investigating, this leads to 36 samples to be arranged
across six Illumina HumanWG6 V3 BeadChips. Clearly
it would not be desirable to confound levels of starting
material with BeadChips as we would be unable to dis-
tinguish our comparison of interest from technical varia-
tion. However it is desirable that our data resemble data
from a ‘real-world’ experiment else they have no exter-
nal validity and, in general, experiments are conducted
on BeadChips using only one level of starting material.
Our design was chosen to address this tension
between internal and external validity. Each BeadChip
was run with samples from two starting quantities of
RNA (three samples from both chosen starting quanti-
ties), and each possible combination of the two starting
quantities was run once and only once amongst the six
BeadChips. Full details of the design are given in Section
1 of Additional File 1.
Laboratory methods
Stock UHRR tubes were prepared following manufac-
turer’s recommendation and pooled to create a stock of
1 mg/ml; Brain RNA was received at 1 mg/ml. The
quality was checked using the Agilent Bioanalyser. The
RNA was accurately diluted to a working stock of
100 ng/μl and the dilution series was created to the spe-
cifications given above. The minimum pipetting volume
used was 10 μl.
The Illumina TotalPrep-96 Kit (4397949) was used to
process the samples using the range of input concen-
trations in question. For the 50 ng and 10 ng input
quantities a 1:10 dilution of working RNA was used.
Quality and quantity of the cRNA was checked before
proceeding with hybridisation to Human WG-6 V3
BeadArray. The Illumina WGGX DirectHyb Assay
Guide (11286331 RevA) protocol was followed for
hybridisation, washing and scanning of the BeadArray,
with the scanner set to return bead-level data (Addi-
tional File 1, Section 2). Quality assessment was
achieved via examination of metrics files (Additional
File 1, Section 3), agreement with previous MAQC
data sets (Additional File 1, Section 4), and perfor-
mance of housekeeping controls (Additional File 1,
Section 5).
Preprocessing and statistical analysis
Illumina BeadScan files were processed and analysed
using the beadarray package [18] from Bioconductor.
Arrays were pre-processed on the log2-scale on a per-
array-section basis. BASH [19] was used to remove
high-frequency spatial artefacts, followed by outlier
removal (outliers being defined as observations more
than three median absolute deviations from the med-
ian), and expression detection score calculation. The
detection score is a standard measure for Illumina
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empirical estimate of the p-value for the null hypoth-
esis that there is no expression. Between-array-section
quantile-normalization was performed within each
starting material level, and a non-linear regression
model fitted across dilution levels within each starting
RNA level.
Our approach demands reporting of raw, bead-level,
Illumina data, which exceeds the MIAME requirements.
As popular repositories are not designed for the storage
of raw (bead-level) data from random arrays, the files
are available to download from our website at http://
www.compbio.group.cam.ac.uk/Resources/Dilution/Dilu-
tion.html.
Statistical model
A previously proposed [20] non-linear model was used
as the theoretical model for the dilution curve:
EU B mrp m rp m rp mrp =+ − + log ( ( ) ) 2 1 cc  (1)
where Emrp is the observed (normalized) log-intensity
for probe p at starting RNA quantity r in mixture level
m, cm is the proportion of the mixture that is UHRR,
Urp is the intensity associated with probe p at starting
RNA level r in the UHRR sample, and Brp is similarly
defined for the Brain sample. The mrp are independent
measurement errors with mean zero and standard devia-
tion srp.
This model implicitly assumes a linear relationship
between quantity of RNA and measured intensity. This
assumption is known not to hold over the full range of
observed intensities for microarrays [21], and specifically
for Illumina BeadArrays [14]. While some models allow
for non-linearity [22], they do not relate it to the known
physico-chemical causes. To do so would be difficult
and, in any case, would not obviously be advantageous
in our situation.
The model can be rewritten in terms of Δrp = Urp
- Brp,
EB mrp m rp rp mrp =+ + Δ log ( ) 2 c  (2)
and we fit this model in R using the nls() function,
weighting each observation by the number of beads that
contributed to the observation. Under this formulation,
it is clear that the test of Δ =0f r o mt h esummary.
nls() function in R provides an approximate and
quick test of a difference in log-intensities.
Restricting the analysis-group of bead-types
We have re-annotated the bead-types on the array [23],
and have identified 23, 562 “perfect” bead-types (using
the August 2009 annotation). These are bead-types that
have a full 50 mer match to a reliable transcript, and do
not possess additional undesirable properties (e.g. map-
ping to transcripts masked by repeat regions, having a
non-unique transcriptomic match, mapping to tran-
scripts that do not align well to the reference genome,
etc.). Additionally, we define an ‘analysis-group’ of bead-
types as a subset of these perfect bead-types that possess
two further properties: 1) That their GC content is con-
ducive to hybridization (i.e. in the range of 20-35 bases),
which excludes a further 506 bead-types, and 2) That
they occur at least six times on each array-section (see
Additional File 1, Section 6). All analyses will be
restricted to this ‘analysis-group’ unless otherwise stated.
Results
Numbers of beads
The random assembly of Illumina arrays is often a vir-
tue, but prevents the conduct of true replicate experi-
ments. In particular, the number of usable beads on
each array can vary, and will influence performance.
T h e r ea r ean u m b e ro fr e a s o n sw h yd i s p a r i t i e se m e r g e .
Not all beads are decoded by Illumina when the array is
manufactured, (which alone leads to the 10 ng experi-
ment having approximately 80, 000 beads more per
array-section than the 100 ng experiment). Further
beads are ‘lost’ due to spatial artefacts and to beads
being classed as outliers during summarization. The
numbers in our experiment are given in Table 1.
It has been observed previously that spatial artefacts
can be associated with nearby regions where beads are
non-decoded [24], so it may not be coincidental that the
Table 1 Numbers of beads
Quantity of starting RNA: 250 ng 100 ng 50 ng 10 ng
Total decoded 18,801,235 17,835,076 17,926,750 19,274,434
Removed by BASH 200,459 408,721 284,088 50,449
Removed in summarization 651,323 614,495 603,619 582,345
Remaining 17,949,453 16,811,860 17,039,043 18,641,640
In analysis-group bead-types 7,963,638 7,475,940 7,563,440 8,248,259
Summing across all array-sections in the four experiments, we list the total numbers of beads (as decoded by Illumina), the numbers we remove as being in
spatial artefacts using BASH [19], those removed as being outliers in the summarization, the remainders, and the numbers remaining that lie in the analysis-
group of bead-types.
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est to spatial artefacts. The differing numbers of beads
may cause concern, although it should be noted that the
median number of replicates for a bead-type only varies
from 21 for the 10 ng experiment to a still very healthy
19 for the 100 ng experiment. The lack of monotonicity
is also helpful; the trends that we show do not correlate
with the total bead-numbers, suggesting that these num-
bers are not driving the results. Whilst we take 250 ng
of starting RNA as our gold standard for comparison,
we can also gain reassurance through comparisons to
the 100 ng experiment which contained fewest beads.
As noted above, we restrict analyses to an analysis-
group containing only ‘perfect’ bead-types, with desir-
able GC composition and at least six beads on each
array-section. This reduces the number of bead-types
considered to 21, 627. This also has a marginal effect on
improving the balance between experiments in terms of
the numbers of beads analysed.
Detection of expression
In Table 2 is presented a summary of agreement between
experiments for the detection of expression (using a
significance level of < 0.01) for the analysis-group (see
also Additional File 1, Section 7). If no bead-types were
truly expressed, we would expect to see 3, 579 apparently
showing expression in at least one array-section and nine
showing expression in both UHRR and brain. Even
acknowledging this, we see that a substantial number of
the analysis-group show expression above negative-con-
trol levels.
Naturally, any bead-type that shows expression in both
Brain and UHRR should show expression in all mixtures
of those two samples, and we see that the proportion of
bead-types satisfying the former that are also returned
by the latter exceeds 80% for the 250 ng, 100 ng and
50 ng experiment but reduces to below 70% for the
10 ng experiment. Agreement between experiments is
reported in Table 3, and is encouraging. Performance in
terms of sensitivity while not perfect at 100 ng only
decreases dramatically when we reach 10 ng, but here
still returns 2/3 of the bead-types that were detected in
both UHRR and Brain using 250 ng. Notably, the false
discovery rate is fairly constant, staying below 10% even
at 10 ng. Thus while one will detect expression in fewer
bead-types using less starting RNA, the validity of that
which is detected is preserved.
Expression of control bead-types
The detection p-values for expression depend on the
performance of negative control bead-types for their
calculation. This platform has 759 negative control
bead-types, which should have no match to the human
transcriptome. Due to the nature of the calculation, at
least seven (1%) of these will themselves apparently
detect significant expression. Table 4 summarizes the
numbers seen in our experiments. We see markedly
more than seven negative control bead-types being
called as ‘detected’, and far more than would be
expected by chance being consistently called as detected.
Such observations could have explanation other than
the bead-types showing specific signal. For instance,
thermodynamic variation could lead to some negative
control bead-types regularly being called as ‘detected’,
but evidence of differential expression is harder to
explain. Using Benjamini-Hochberg control for false dis-
covery rate, there are still three negative control bead-
types for the 250 ng starting material experiment (two
f o r1 0 0n g ,e i g h tf o r5 0n g ,a n df o u rf o r1 0n g )t h a t
show differential expression. The greatest evidence of a
negative control showing specific hybridization is for
bead-type ILMN_1343923 (Additional File 1, Section 8).
The amount of starting RNA varies between experi-
ments, but the amount of cRNA used is the same in
every case, so there is no reason to anticipate overall
changes in intensity levels. However, the intensity levels
change for both the housekeeping bead-types (bead-
types that target genes EEF1A1, GAPDH, TXN, ACTB,
TUBB2A, RPS9, UBC) and the negative control bead-
types, suggesting that the levels of non-specific hybridi-
zation vary according to the amount of starting material
(Table 4, Figure 1).
The log-intensity levels for the housekeeping control
bead-types decrease at a greater rate than those for the
negative control bead-types (except when saturation
effects are apparent). Thus the log-fold-change in inten-
sities from housekeeping gene to negative control
(a measure of signal to noise) decreases with the
Table 2 Expression detected
Quantity of starting RNA: 250 ng 100 ng 50 ng 10 ng
...at least one array-section 15,880 15,597 15,691 14,090
...both UHRR and Brain 11,992 11,248 10,965 8,775
...all array-sections 9,964 9,178 8,996 5,975
mean number of array-sections 6.94 6.59 6.47 4.95
For each of the four experiments, we report the number of analysis-group bead-types for which expression was detected in at least one of the 18 array-sections,
at least one of the two 100% UHRR array-sections and at least one of the two 100% Brain array-sections, and in all 18 array-sections. Additionally for the analysis-
group bead-types, we report the mean number of array-sections out of 18 in which expression is detected.
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apparent even at 100 ng levels of starting material.
Other control bead-types on the Illumina BeadArray
platform are not sample dependent, and do not vary
considerably between starting quantities of RNA.
Magnitude of expression
Figure 2 shows MA plots for the analysis-group of bead-
types comparing single array-sections of 100% UHRR.
Although true agreement with intensities from 250 ng is
clearly poor when small amounts of starting material
are used, the rank-correlation between array-sections
remains high even for 10 ng of starting RNA (Table 5),
suggesting that it may be possible to normalize samples
arising from different starting levels of RNA.
It is also clear from Figure 2 that intensities generally
decrease with the quantity of starting RNA, as was observed
specifically for the control bead-types. This loss of signal
leads to an apparent diminishing of technical biases (e.g. if
all signal were lost then we would cease to observe the
diminishment of signal as target locations become more 5’
along the gene), which should not be mistaken for a benefit.
Differential expression
The number of bead-types identified as showing differen-
tial expression (p < 0.001, for the non-linear model),
decreases with the amount of starting material much
as did the number for which expression was detected
(Table 6). Naturally, differential expression implies
expression, so we might expect to see the numbers for
differential expression bounded by the numbers we saw
for expression. The decline in numbers of bead-types for
which differential expression is noted is more marked
than would be required simply by this constraint. More-
over we should note that due to the nature of the two
tests, it is entirely possible to detect differential expres-
sion across the set of array-sections, but not detect
expression in any individual array-section (Additional
File 1, Section 9): evidence that the filtering of bead-types
based on expression-detection scores requires caution.
Once more, the sensitivity (defined as for expression
detection) is high with a drop-off only when 10 ng of start-
ing RNA are used, and the FDR (defined as for expression
detection) remains low across all quantities of starting
RNA (Table 7). If we break down the comparison by the
magnitude of differential expression (taking 250 ng as the
gold standard and comparing the log-expression between
100% UHRR and 100% Brain), then it is apparent (Figure
3) that one pays a price for using the 10 ng level of starting
material across the full range of log-fold changes (Addi-
tional File 1, Section 10). The performance of the 100 ng
and 50 ng starting levels is better, and matches 250 ng
outside the range of 0.25 to 1.25. Within that range, they
return a lower proportion of bead-types as being differen-
tially expressed, while the 100 ng level of starting material
also outperforms the 50 ng level.
Signal to noise
The variance of observations is not independent of their
value. Since expression levels decrease as the quantity of
starting RNA decreases, it is not possible to assess the
change in variance as the quantity of starting RNA
decreases, without simultaneously considering the level
of expression.
From the non-linear model we can compare the esti-
mate of the difference in expression levels to the estimated
Table 3 Consistency in expression detection between
quantities of starting RNA
reference experiment
test experiment 250 ng 100 ng 50 ng
10 ng 0.67/0.09 0.71/0.09 0.73/0.09
50 ng 0.86/0.06 0.89/0.09
100 ng 0.86/0.08
For the numbers of bead-types with detected expression in both 100% Brain
and 100% UHRR reporting “X/Y” where X is the proportion of bead-types
reported for the reference experiment also reported for the test experiment
(e.g. a measure of sensitivity), and Y is the proportion of bead-types reported
by the test experiment that were not reported by the reference experiment
(e.g. FDR). So for example, taking 250 ng as a gold-standard, for this detection
measure the 100 ng experiment has 86% sensitivity and an FDR of 0.08.
Table 4 Control bead-type summary
Quantity of starting RNA: 250 ng 100 ng 50 ng 10 ng
Negative controls detected in UHRR 37 32 20 0
Negative controls detected in Brain 35 40 29 24
Negative controls detected in all array-sections 10 6 2 0
Negative controls detected in at least one array-section 88 89 98 99
Negative controls: median log-intensity UHRR 5.78 5.79 5.73 5.58
Negative controls: median log-intensity Brain 5.80 5.82 5.72 5.58
Housekeeping controls: median log-intensity UHRR 13.46 13.14 13.09 11.32
Housekeeping controls: median log-intensity Brain 12.47 12.52 12.03 10.64
Giving a) the numbers of the 759 negative-control bead-types that show expression in one or more array-sections, and b) median log-intensities for negative-
control and housekeeping bead-types in 100% UHRR and 100% Brain array-sections.
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plications of the variance and fluorescence levels changing
in a dependent manner as the amount of starting material
changes. Considering only the analysis-group of bead-
types, the median ratios of standard error to estimate are
0.23, 0.28, 0.31 and 0.52 for 250 ng, 100 ng, 50 ng and 10
ng of starting RNA respectively. The median ratios of the
two signal to noise ratios are 1.12, 1.16 and 1.76 for 100
ng, 50 ng or 10 ng respectively comparing to a reference
starting quantity of 250 ng.
Discussion
Meta-analysis
Inevitably, there will be occasions when we wish to com-
bine data sets generated using different quantities of start-
ing material, possibly because we are performing a meta-
analysis across different experiments, or possibly because
not all samples within a single experiment can supply the
desired quantity of starting RNA. Our analysis has, so far,
considered the different quantities of starting material in
this study as being different experiments, but we will now
briefly consider strategies for combining them.
Consider if samples were run in strata of starting RNA, e.
g. we have an experiment where some samples were run
using 250 ng, while others were run using 50 ng. The strata
were not balanced in terms of experimental design, so we
may not wish to obtain two simple estimates for the para-
meters of interest (one from each stratum) and then com-
bine the estimates. Our strategy for analysis may depend
on whether some samples had been run in both strata.
Consider further that we only have Brain run at 50 ng
a n dU H R Ra t2 5 0n g ,a n dw ew i s ht ot r a n s f o r mt h e
50 ng Brain data for comparison with UHRR. Essentially
we wish to simulate a 250 ng Brain data set from this
restricted data set, and can use the fact that we do have
Brain run at 250 ng to assess the performance. We will
consider both the scenario where we have only the two
samples with which to work, and a second where we
have additionally run UHRR at 50 ng.
If we are in this first scenario, then there is little
option but to normalize between the samples. The high
rank correlation we have observed between data arising
from different starting amounts of RNA gives cause for
optimism that a simple quantile-style normalization of
the 50 ng data to the expression profile of the 250 ng
data will prove successful. With data available from
samples run at both starting levels, we can use the 50
ng UHRR and 250 ng UHRR samples to estimate the
bias due to starting RNA quantity (via fitting a locally
smooth regression) and can then project the 50 ng
Brain sample with that model to obtain our prediction
for how a 250 ng Brain sample would look. Such an
approach shows a marginal improvement over the basic
attempt in our example (Figure 4).
Figure 1 The change in control bead-type performance with
quantity of starting RNA. Illustrating for array-sections hybridized
to either 100% Brain or 100% UHRR, the log2-intensities seen for
selected control bead-types. The medians, ranges and interquartile
ranges of the 759 negative control bead-types are illustrated with
box and whisker plots, while the profiles of the seven housekeeping
controls are also indicated.
Figure 2 The change in expression with quantity of starting
RNA. Depicted are “MA” plots where the difference of two log2-
intensities (y-axis) is plotted against the average of the log2-
intensities. Here we show the agreement of log2-intensity between
a section of the 250 ng experiment and all four levels of starting
RNA (using replicate array-sections to make the 250 ng vs 250 ng
comparison).
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small improvement to our ability to transform the 50 ng
Brain data and in a real experiment running 50 ng of an
additional sample may provide greater value to the ulti-
mate analysis. We should be wary of trying to use a
sample for both bias-estimation and analysis as there
will be a lack of independence between these samples
and all those that are bias-corrected using the results.
Moreover the small improvement we see here, over the
simpler quantile-normalization style approach, comes
using samples that have large numbers of expressed
genes. For bias correction of this nature to be useful, we
need to observe a wide range of log-intensities which in
turn requires large numbers of genes to be expressed.
Thus the appropriateness of this more complicated
method will be dependent on the size of the experiment
and the nature of the samples being hybridized.
Implications for experimental design
A number of implications for experimental design are
obvious. It is clear that all things being equal, of the
range of starting quantities of RNA considered here, it
is preferable to use 250 ng. If there are limitations to
the amount of starting RNA available, then the more
starting material used the better (within this range
examined). Should the amount of available RNA differ
between samples then more subtle decisions are
Table 5 Squared rank correlations
Quantity of starting RNA
250 ng 100 ng 50 ng 10 ng
250 ng 0.954 0.933 0.921 0.784
100 ng 0.933 0.916 0.789
50 ng 0.924 0.784
10 ng 0.797
Giving the square of Spearman’s rank correlation for the intensities of the analysis-group bead-types between 100% UHRR array-sections.
Table 6 Differential expression detected
250 ng 100 ng 50 ng 10 ng
amongst all bead-types 15,753 (32%) 14,361 (29%) 13,741 (28%) 9,579 (19%)
amongst analysis group 11,021 (51%) 10,169 (47%) 9,788 (45%) 7,084 (33%)
Showing the numbers (and percentage) of bead-types from the complete set of 49,575 for which differential expression between Brain and UHRR was detected.
Also showing the same measures for the analysis-group bead-types.
Table 7 Consistency in detection of differential
expression between quantities of starting RNA
reference experiment
test experiment 250 ng 100 ng 50 ng
10 ng 0.62/0.04 0.67/0.04 0.69/0.05
50 ng 0.83/0.07 0.88/0.08
100 ng 0.86/0.06
For the numbers of bead-types for which differential expression between
UHRR and Brain was detected we report “X/Y” where X is the proportion of
bead-types reported for the reference experiment also reported for the test
experiment (e.g. a measure sensitivity), and Y is the proportion of bead-types
reported by the test experiment that were not reported by the reference
experiment (e.g. FDR). So for example, taking 250 ng as a gold-standard, for
this detection measure the 100 ng experiment has 86% sensitivity and an FDR
of 0.06.
Figure 3 The power to detect differential expression by
quantity of starting RNA. Illustrating, for the analysis-group of
bead-types, the increased ability to detect large log2-fold changes
(for all levels of starting RNA), and how the relationship (between
that ability and the size of the log-fold change) varies with the
quantity of starting RNA. The empirical log fold change calculated
from the 250 ng experiment is depicted on the x-axis, which is
divided into 50 bins, each containing 2% of the bead-types
(indicated by the vertical lines). On the y-axis are indicated 95%
confidence intervals for the proportion of bead-types in each bin
for which differential expression will be detected.
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can infer that if using 100 ng or 50 ng then the sample
s i z ew o u l dn e e di n f l a t i n gb yaf a c t o ro fa tl e a s t1 . 2t o
achieve the same performance, while if using 10 ng,
then in the region of three times the numbers will be
required. Thus, when we have the choice and free from
other pressures, reducing the starting RNA level is only
desirable if it allows sample numbers to be increased by
these factors.
The combination of multiple starting RNA levels in one
experiment will be problematic. If we wish to normalize
using data from the same sample hybridized from multiple
quantities of starting RNA, then clearly we must stratify
samples into a few starting quantities. If we do not have,
or do not wish to make, recourse to replicate samples
hybridized from several RNA quantities, and are simply
going to normalize samples together, then there is merit
in using as much starting RNA as possible for each sam-
ple, as was noted in the previous section.
In this scenario, where all samples are independent, it
would still be hard to criticize a design that opted for a
fixed number of starting levels, especially if this came at
minimal cost to quality (i.e. 250 ng reduced to 220 ng
but not to 10 ng) and allowed balance of experimental
criteria to be achieved within each stratum of starting
quantity. Such an approach is suboptimal by our criter-
ion, but may be more robust to those unexpected events
that befall real-world experiments.
Conclusions
We have presented a bead-level Illumina BeadArray
dilution control experiment that will be a valuable
resource for the Illumina analysis community. As
intended, the experiment also answers an important
experimental question regarding the required levels of
starting RNA, however it also allows for a number of
questions to be addressed regarding experimental
design when large quantities of RNA are difficult to
obtain.
We have shown that reliable signal is obtainable
u s i n ga sl i t t l ea s1 0n go fs t a r t i n gR N A .H o w e v e rw e
have also seen that lower levels of starting RNA are
associated with a bias in expression levels (which may
be correctable), and drop in sensitivity (which will
not be).
This increase in noise implies that, if using less start-
ing RNA, more samples would be needed in an experi-
ment to achieve the same levels of precision. However,
it seems that few false discoveries result from using
even as little as 10 ng of starting RNA. Thus while a
small experiment using a low starting quantity of RNA
may fail to identify many subtle changes, one can have
confidence in any changes that are reported.
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Figure 4 The performance of alternative normalization
strategies. The performances of different strategies for normalizing a
50 ng Brain array-section for comparison to a 250 ng UHRR array-
section are illustrated. For the analysis-group bead-types, with a 250
ng Brain array-section as a reference, we determine the squared
differences between our prediction of log2-intensity and the
reference and illustrate the cumulative distribution of those
differences. The first prediction uses a basic quantile-style
normalization where the 50 ng Brain array-section is transformed to
take the distribution of intensities seen on the 250 ng UHRR array-
section. A more complicated prediction making use of a 50 ng UHRR
section is also illustrated. For reference we give the agreement
between replicate 250 ng Brain array-sections, representing the gold-
standard that could be achieved by any method.
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